Results 201 to 210 of about 9,409 (259)

Socioeconomic Inequalities in Receipt of Curative‐Intent Treatment and Survival After Surveillance‐Detected Hepatocellular Carcinoma: A Nationwide Cohort Study

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Socioeconomic inequalities in receipt of curative‐intent treatment and survival persist among individuals with surveillance‐detected HCC within a universal healthcare system. These findings suggest that surveillance alone is insufficient to ensure equitable outcomes and highlight the need for strategies addressing social determinants across the care ...
Hannes Hagström   +6 more
wiley   +1 more source

Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report. [PDF]

open access: yesMol Clin Oncol, 2017
Mizutani K   +7 more
europepmc   +1 more source

BK virus-associated collecting duct carcinoma of the renal allograft in a kidney-pancreas allograft recipient. [PDF]

open access: yesOncotarget, 2018
Dao M   +6 more
europepmc   +1 more source

Pharmacological activation of NO‐cGMP signalling attenuates metabolic dysfunction‐associated steatohepatitis

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Metabolic dysfunction‐associated steatohepatitis (MASH) is linked to activation of hepatic stellate cells (HSCs) to α‐smooth muscle actin–positive myofibroblasts that produce collagen and proinflammatory cytokines. Quiescent HSCs express the NO‐cGMP signalling axis.
Krithika Rajeeth   +14 more
wiley   +1 more source

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Spatial Transcriptomics and Bulk RNA‐Seq Analysis Revealed Molecular Classification of Invasive Lobular Carcinoma

open access: yesCancer Science, EarlyView.
Spatial transcriptomics and bulk RNA‐seq data analysis revealed the molecular characteristics of invasive lobular carcinoma (ILC). ILC was classified into three clusters: proliferative, immunoreactive, and stromal‐rich, with different prognoses. ABSTRACT Invasive lobular carcinoma (ILC) is a special type of breast cancer.
Momoko Tokura   +9 more
wiley   +1 more source

Bile‐Derived Exosomal miR‐196a/‐196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer

open access: yesCancer Science, EarlyView.
Bile‐derived exosomal miR‐196a and miR‐196b are identified as novel biomarkers for biliary tract cancer. Serum miR‐196a levels are significantly elevated in advanced disease with metastasis, while both miRNAs contribute to tumor progression by promoting cancer cell proliferation and invasion.
Naotaka Kugiyama   +20 more
wiley   +1 more source

KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4

open access: yesCancer Science, EarlyView.
KYNU is upregulated in gastric cancer cells and activates the PI3K/Akt pathway, leading to PF4 secretion. PF4 drives nonclassical macrophage polarization with high expression of S100A8 and MMP7, which promotes tumor proliferation, migration, and invasion while suppressing phagocytosis, thereby accelerating gastric cancer progression.
Xilun Cui   +4 more
wiley   +1 more source

Genetic Evolution in BRCA1‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis

open access: yesCancer Science, EarlyView.
Multi‐region sequencing of 57 BRCA1‐associated breast cancers identified TP53 as the dominant initial driver, defining a triple‐negative subgroup with biallelic BRCA1 loss and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers and linked to reduced HRD, EMT activation, and a trend toward worse survival.
Li Hu   +13 more
wiley   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy